Introduction {#sec1-1}
============

Oral tongue squamous cell carcinoma (OTSCC) is the most common cancer diagnosed in the oral cavity, accounting for 25-40% of all oral malignancies ^[@ref1]^. In the United States, almost 17,000 new cases and 2,500 OTSCC-related deaths are expected in 2018 ^[@ref2]^. OTSCC is burdened by significant morbidity and mortality and its incidence is continuously arising, particularly in young subjects ^[@ref3][@ref4]^. Despite advances in detection and treatment, 5-year overall survival (OS) and disease-free survival (DFS) are steadily in the range of 50-60% ^[@ref1][@ref5]^. The pathogenesis of OTSCC is related to several factors involved in the carcinogenetic process such as heat, chronic injuries, poor oral hygiene, cigarette smoking and alcohol consumption ^[@ref6]^. Moreover, OTSCC is characterised by a high frequency of lymphatic metastasis, a high risk of recurrence and the possibility to develop drug resistance to chemotherapy during treatment ^[@ref7]^.

Clinical outcomes strictly correlate with disease stage and lymph node spread at the time of presentation. Moreover, some characteristics, such as tumour depth, vascular and perineural invasion (PNI) and tumour budding are widely recognised as prognostic factors ^[@ref8]^. Conversely, the impact on survival of other features, including anatomic site, age, tumour grade and some biological markers is still uncertain, depending on the great variability among reports in the literature, which is mainly represented by limited case series ^[@ref14][@ref15]^. A further confusing factor is the evaluation of oral tongue cancers either in series including base of tongue tumours or in series reporting a combination of cancers from different sites in the head and neck district. The management and outcomes of each subsite tend to be different ^[@ref16][@ref17]^.

Surgery is the standard treatment for early OTSCC. Locally and loco-regionally advanced cases can be treated by surgery and adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) according to the presence of risk factors such as lymph node metastases, extra-nodal extension (ENE) and involved surgical margins ^[@ref18][@ref19]^. Alternatively, primary concomitant CRT can be offered to patients with the aim of sparing organ function.

In this study, we retrospectively evaluated the role of surgery on clinical outcomes in a cohort of patients affected by OTSCC treated at our institution in the last decade.

Materials and methods {#sec1-2}
=====================

Study setting {#sec2-1}
-------------

This was a monocentric, retrospective, independent study on patients with surgically-resected OTSCC treated and followed at San Paolo Hospital (Milan, Italy) between July 2004 and December 2012. Demographic data, risk factors, tumour characteristics and disease status were obtained from medical records. The study was approved by local Ethics Committee. All patients alive at the time of data collection and/or analysis signed an informed consent for use of personal data.

All pathological specimens were reviewed by two independent pathologists to confirm diagnosis and evaluate tumour depth, grade of tumour cell differentiation, presence of perivascular invasion and PNI, marginal status and the presence of ENE. Tumour size and nodal involvement were categorised according to the American Joint Committee on Cancer (AJCC) TNM staging (7^th^ Edition, 2009).

All cases were previously discussed and evaluated by a multidisciplinary team, consisting minimally of an oncologist, surgeon, radiotherapist, and dedicated radiologists and pathologists. Patients with localised or loco-regional disease were treated by radical surgery, consisting of tumour resection +/- lymph node neck dissection. The decision to proceed with lymph node neck dissection was taken after careful evaluation of nodal involvement at baseline imaging or as a consequence of pathological diagnosis. Patients with a tumour depth greater than 3 mm were deferred to elective neck dissection ^[@ref20]^. Patients with positive or close surgical margins, defined as the presence of tumour cells at the margin or within 5 mm, received surgical re-intervention (whenever possible) or RT/CRT. Patients at risk of relapse (node metastases, ENE, critical margins) were treated with adjuvant RT or CRT, according to national and international guidelines ^[@ref18][@ref21]^.

Patients were then referred to the Oncology Unit for follow-up. Each follow-up visit included physical examination, blood tests and CT scan or MRI of the head and neck region (every 3 months during the first 2 years, and then every 6 to 12 months).

Study population {#sec2-2}
----------------

Eligibility criteria were: (1) age ≥18 years; (2) pathologically confirmed diagnosis of resected OTSCC; (3) ECOG performance status (PS) of 0-2; (4) available data on risk factors, tumour characteristics and patient outcomes. Patients with (1) distant metastases at baseline imaging and/or (2) primary tumour of the tongue base or other sites of the head and neck district were not included in the study.

Objectives {#sec2-3}
----------

The main objective of the study was to investigate the impact of clinical and pathological characteristics on survival of patients with completely resected OTSCC. The primary endpoint was disease-free survival (DFS), defined as the time from surgery until the date of relapse, date of death or last follow-up visit, whichever occurred first. The secondary endpoint was overall survival (OS), defined as the time from surgery until the date of death.

Immunohistochemistry for p16 and p53 {#sec2-4}
------------------------------------

Immunohistochemistry (IHC) was performed according to standard protocols at our institution. Formalin-fixed, paraffin-embedded tissue sections (4 μm) from OTSCC tumour samples were used as substrates in IHC reactions. IHC staining with monoclonal antibodies (mAbs) labeled for p16^INK4A^ (clone E6H4, Dako, Glostrup, Denmark) and p53 (clone DO-7, Thermo Fisher Scientific, MA, US) was performed, as previously described ^[@ref22][@ref23]^. Tumour slides were evaluated and classified by two pathologists. Positive p16 and p53 expressions were defined as the presence of strong and diffuse nuclear and cytoplasmic staining in more than 70% of tumour cells.

Statistical analysis {#sec2-5}
--------------------

Demographic and clinical-pathological features were analysed using descriptive statistics. Absolute frequency and percentage were used to describe categorical variables, while median and interquartile range were reported for continuous variables. DFS was estimated using the Kaplan-Meier method and differences between variables were assessed with the Log-Rank test (univariate analysis). Cox proportional hazard regression models were used to evaluate the association between demographic and clinical-pathological variables and the survival endpoint. Statistical tests were two-sided and *p*-value less than 0.05 was considered as statistically significant. All the analyses were performed using SAS software v. 9.4 (SAS Institute, Cary, NC, US).

Results {#sec1-3}
=======

Between July 2004 and December 2012, 106 OTSCC patients were included in the study. Patient characteristics are summarised in [Table I](#table001){ref-type="table"}.

Median age was 61 years (interquartile range = 51-69). Sixty-eight patients (64.1%) were male. Most patients presented with pT1 and pT2 disease (n = 56, 52.8%, and n = 31, 29.2%, respectively), while only a minority with pT3 and pT4 disease (n = 5, 4.7%, and n = 14, 13.2%, respectively). A tumour depth greater than 3 mm was found in 74 cases (69.8%). Nodal involvement was detected in 37 patients (34.9%), with the presence of ENE in 16 tumours (15.1%). Tumours were well/moderately or poorly differentiated in 83 (78.3%) and 23 (21.7%) cases, respectively. PNI and perivascular invasions were detected in 13 (12.2%) and 9 (8.4%) tumours, respectively. Close or positive surgical margins were present in 17 (16.0%) cases.

Overall, 63 patients (59.4%) were diagnosed with stage I or II disease, while stages III and IV were present in 14 (13.2%) and 29 (27.4%) cases, respectively. Regarding neck management, 82 patients (77.3%) underwent neck dissection, concomitant to or deferred with respect to radical surgery. Sixty patients did not receive any postoperative treatment. Conversely, 27 (25.5%) and 19 (17.9%) patients received postoperative RTX or CRT, respectively, according to the presence of risk factors as previously described.

To evaluate any difference between age and clinical-pathological features, patients were subdivided into 2 age groups: \<40 and ≥40 years (n = 14, 13.21% and n = 92, 86.79%, respectively). No significant differences in terms of tumour characteristics were observed between the two groups.

Survival analysis {#sec2-6}
-----------------

Three patients were excluded from survival analysis due to the lack of information about the time of disease progression and/or death.

After a median of follow-up of 8.9 years (5.3-11.4), 22 (21.4%) events occurred, including 11 (10.7%) deaths ([Table II](#table002){ref-type="table"}).

In the first five years of follow-up, 13 tumour relapses, including 11 deaths, were observed. The 5-year DFS and OS rates were 87.4% and 91.3%, respectively.

Using log-rank test, no significant differences in terms of DFS were observed for age groups (p = 0.222), smoking status (p = 0.193), tumour size (p = 0.407), nodal involvement (p = 0.379), tumour depth (p = 0.161), vascular invasion (p = 0.291), tumour differentiation (p = 0.062) and surgical margins (p = 0.064). Conversely, the presence of ENE (p = 0.023) and PNI (p = 0.003) were significantly correlated with shorter DFS ([Fig. 1](#fig001){ref-type="fig"}).

In multivariable Cox regression analysis, the presence of ENE \[Hazard Ratio (HR) 2.87, 95% CI 1.11-7.42, p = 0.03\] and PNI (HR 3.85, 95% CI 1.49-9.96, p = 0.006) were significantly associated with a higher risk of disease recurrence ([Table III](#table003){ref-type="table"}).

Regarding OS, in the multivariable Cox regression analysis, no significant differences were detected for age groups (p = 0.837), smoking status (p = 0.526), PNI (p = 0.178), ENE (p = 0.961), nodal involvement (p = 0.553), tumour depth (p = 0.515), tumour size (P = 0.751), vascular invasion (p = 0.753), tumour differentiation (p = 0.087) and surgical margins (p = 0.702).

Analysis for p16 and p53 expressions {#sec2-7}
------------------------------------

Of the 106 tumours examined, 75 tissue samples were available for evaluation of p16 and p53 expression, which was present in 12% (n = 9) and 46% (n = 40) of the samples, respectively. However, no significant correlations with clinical features were observed.

In univariate analysis, no differences in terms of DFS and OS were observed between p16+ and p16- (p = 0.125), as well as between p53+ and p53- tumours (p = 0.213).

Discussion {#sec1-4}
==========

Radical surgery, eventually followed by RT or CRT, is the standard treatment for OTSCC leading to about a 70% probability of cure in the early stages ^[@ref18]^. Loco-regionally advanced disease still has a dismal prognosis and less than half of patients have a real chance of cure ^[@ref24]^. An integrated approach consisting of multimodality diagnostic and therapeutic workup is mandatory for high risk patients, defined by the presence of aggressive features such as advanced primary tumour (T3 or T4), number and sites of lymph node involvement, ENE, PNI, vascular infiltration, poor tumour differentiation and incomplete surgery ^[@ref8]^. Although many studies have evaluated the role of multimodality treatment in head and neck cancers, only a few have focused on the impact of surgery and (chemo)radiation in tongue cancer exclusively.

We retrospectively analysed 106 OTSCC patients to identify risk factors associated with a reduced survival. The features of our population are in line with data available in the literature. Most of our patients had small tumours (especially pT1 and pT2), but nodal involvement was detected in about one-third of cases.

To detect differences in clinical-pathological features of disease presentation and recurrence, we subdivided the population in two cohorts in relation to age (\< 40 and ≥ 40 years). However, we found no difference between the two age groups. In the 14 patients in the youngest group, only one subject had disease recurrence in the observation period. We are aware that this could be related to the low percentage of young subjects in our population, nonetheless young age seems to consistently correlate with improved prognosis. Regarding survival differences between young and older OTSCC patients, contrasting data have been provided so far. Some authors reported that young subjects present worse survival outcomes than the elderly, justifying more intensive treatments in this subgroup ^[@ref25]^. Conversely, other studies demonstrated the absence of difference in terms of higher risk of disease recurrence or worse survival in young (\< 40 years) OTSCC patients ^[@ref29]^. On the other hand, some authors have highlighted the role of aging in poor prognosis ^[@ref30]^ and the negative impact of comorbidities on elderly patients in terms of OS and postsurgical complications ^[@ref31]^. However, these latter studies were not focused on OTSCC, but included patients with tumours at different head and neck sites. Therefore, the impact of age on OTSCC prognosis has not been well defined and further studies that address this issue are warranted.

In our population, 5-year DFS and OS rates were 87.4% and 91.3%, respectively. These encouraging survival outcomes could be attributed to the post-operative strategies adopted, such as neck dissection and RT or CRT for patients displaying major risk factors. As previously described, patients with tumour depth greater than 3 mm were referred to elective neck dissection ^[@ref20]^ as well as those with positive surgical margins, who received surgical re-intervention or, if technically not feasible, adjuvant CRT. In addition, the presence of ENE was a further absolute indication to adjuvant CRT. Patients with minor risk factors such as pT3 or pT4 primary, N2 or N3 nodal disease, nodal disease in levels IV or V, PNI, vascular embolism or lymphatic invasion underwent adjuvant RTX ^[@ref18][@ref21]^. We did not find any difference in terms of DFS when considering smoking status, tumour size, nodal involvement, tumour depth, vascular invasion, positive surgical margins and cell differentiation.

Moreover, our study did not demonstrate a link between p16 expression and survival, confirming that the prognostic role of human papilloma virus (HPV) infection in OTSCC is not yet clear ^[@ref32][@ref33]^. In addition, p53 expression did not impact on survival. Thus, our study is in good agreement with the recent meta-analysis by Almangush et al., suggesting that p16 and p53 expression have no role as prognostic factors in OTSCC ^[@ref34]^, while their pathogenetic role is unanimously recognised in oropharyngeal cancer ^[@ref35][@ref36]^. To date, no clear prognostic biomarker has been established for OTSCC patients treated with radical surgery. Ongoing research on new biomarkers and genomic determinants might allow better understanding of the factors involved in OTSCC pathogenesis and progression ^[@ref37][@ref38]^.

Notably, tumours presenting with PNI had a higher risk of disease recurrence. PNI has a well-recognised prognostic role and is associated with dismal prognosis in head and neck tumours ^[@ref39][@ref40]^. The presence of ENE also indicates an increased risk of tumour relapse, confirming its role as an independent poor prognostic factor ^[@ref41]^.

Nowadays, high-quality surgery, eventually followed by RTX or CRT according to the presence of risk factors, represents the cornerstone on which long survival of early stage OTSCC is based. As previously described, in our population tumours with PNI and ENE presented a higher risk of disease relapse, underlining their significant role as prognostic factors. Moreover, their presence in tissue samples highlights the need of a careful multidisciplinary evaluation in order to plan the best postoperative therapeutic strategies.

Conclusions {#sec1-5}
===========

Our study, with the limitation of a retrospective analysis, highlights the possibility to achieve high cure rates in OTSCC. PNI and ENE were independently associated with reduced DFS in our population. Survival rates of around 90% can be achieved by strict cooperation of a multidisciplinary team of experts that manages the patient from the first diagnostic approach to completion of treatment and definition of proper follow-up.

Figures and tables {#sec1-6}
==================

![Disease-free survival (DFS) in the overall population (a), and according to age (b), perineural invasion (c) and extracapsular extension (d).](aoi-2019-02-84-g001){#fig001}

###### 

Baseline characteristics (N = 106).

                                   N            \%
  -------------------------------- ------------ ------
  **Age**                                       
      Median (IQR)                 61 (51-69)   
        \< 40 years                14           13.2
        ≥ 40 years                 92           86.8
  **Sex**                                       
      Male                         68           64.1
      Female                       38           35.9
  **Smoker**                                    
      No                           31           29.2
      Yes                          75           70.8
  **Neck dissection**                           
      No                           24           22.6
      Yes                          82           77.4
  **Tumour**                                    
      pT1/2                        87           82.1
      pT3/4                        19           17.9
      pT1                          56           52.8
      pT2                          31           29.2
      pT3                          5            4.7
      pT4                          14           13.2
  **Node**                                      
      pN0/X                        69           65.1
      pN1/2/3                      37           34.9
      pNX                          25           23.6
      pN0                          44           41.5
      pN1                          13           12.3
      pN2                          23           21.7
      pN3                          1            0.9
  **Stage**                                     
      I/II                         63           59.4
      III/IV                       43           40.6
      I                            46           43.4
      II                           17           16.0
      III                          14           13.2
      IV                           29           27.4
  **ENE**                                       
      Missing                      3            2.8
      No                           87           82.1
      Yes                          16           15.1
  **Depth**                                     
      \< 3 mm                      32           30.2
      ≥ 3 mm                       74           69.8
  **Vascular invasion**                         
      Missing                      3            2.8
      No                           94           88.7
      Yes                          9            8.5
  **Perineural** **invasion**                   
      Missing                      3            2.8
      No                           90           84.9
      Yes                          13           12.3
  **Tumour** **differentiation**                
      G1/2                         83           78.3
      G3                           23           21.7
  **Margins**                                   
      No                           89           84.0
      Yes                          17           16.0
  **Postoperative treatment**                   
      None                         60           56.6
      RT                           27           25.5
      CRT                          19           17.9

CRT: chemo-radiotherapy ENE: extra-nodal extension; IQR: interquartile range; RT: radiotherapy.

###### 

DFS and OS events according to different stages of disease.

  Stage   DFS events   OS events               
  ------- ------------ ----------- ----------- -----------
  I       35 (33.9)    10 (9.7)    42 (40.8)   3 (2.9)
  II      15 (14.6)    2 (1.9)     16 (15.5)   1 (0.9)
  III     11 (10.7)    1 (0.9)     12 (11.6)   0 (0.0)
  IV      20 (19.4)    9 (8.7)     22 (21.4)   7 (6.9)
  Total   81 (78.6)    22 (21.4)   92 (89.3)   11 (10.7)

###### 

Cox regression analysis for disease-free survival (DFS).

                                                               N    Events/PY   HR     95% CI       P-value
  ------------------------------------------------------------ ---- ----------- ------ ------------ ---------
  **Age**                                                                                           
    \< 40 years                                                14   1/106       3.26   0.44-24.23   0.25
    ≥ 40 years                                                 92   21/625                          
  **Smoker**                                                                                        
    No                                                         31   4/240       2.03   0.69-5.99    0.20
    Yes                                                        75   18/491                          
  **pT**                                                                                            
    pT1/2                                                      87   17/620      1.52   0.56-4.13    0.41
    pT3/4                                                      19   5/112                           
  **pN**                                                                                            
    pN0/X                                                      69   13/498      1.46   0.62-3.42    0.38
    pN1/2/3                                                    37   9/234                           
  **ENE[\*](#t3-tfn1){ref-type="table-fn"}**                                                        
    No                                                         87   15/625      2.87   1.11-7.42    0.03
    Yes                                                        16   6/86                            
  **Depth**                                                                                         
    \< 3                                                       32   4/245       2.13   0.72-6.30    0.17
    ≥ 3                                                        74   18/487                          
  **Vascular invasion[\*](#t3-tfn1){ref-type="table-fn"}**                                          
    No                                                         94   18/657      1.91   0.56-6.50    0.30
    Yes                                                        9    3/54                            
  **Perineural invasion[\*](#t3-tfn1){ref-type="table-fn"}**                                        
    No                                                         90   15/652      3.85   1.49-9.96    0.006
    Yes                                                        13   6/59                            
  **Grading**                                                                                       
    G1/2                                                       83   14/591      2.24   0.94-5.34    0.07
    G3                                                         23   8/141                           
  **Margins**                                                                                       
    No                                                         89   16/645      2.38   0.93-6.11    0.07
    Yes                                                        17   6/86                            

\* 3 patients with missing information. CI: confidence interval; HR: hazard ratio; ENE: extra-nodal extension; PY: per-year.
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